07/26/2022
Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to [email protected].
07/18/2022
Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA™ (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)
06/22/2022
Mycovia Pharmaceuticals Announces Positive New Clinical Findings Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC)
05/05/2022
Mycovia Pharmaceuticals to Host Product Theater for VIVJOA™ (oteseconazole) during 2022 American College of Obstetricians and Gynecologists Annual Meeting
04/28/2022
